Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at Cleveland Clinic, was the lead author on a followup study to the landmark WRAP-IT trial ...
Cardiac Resynchronization Therapy Devices (CRT)
Cardiac Resynchronization Therapy Devices (CRT) are cardiac electrophysiology (EP) systems that include a small electronic device that is surgically implanted into a pocket of skin to help both ventricles contract together. They are also called biventricular pacemakers. These systems can be used for pacing only, or can include a built-in defibrillator.
-
-
September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control in reducing mortality in severely symptomatic permanent atrial fibrillation (AF) ...
-
Samir Saba, M.D., co-director of the University of Pittsburgh Medical Center Heart and Vascular Institute, and chief, Division of Cardiology, explains the SMART MSP (Multi-Site Pacing) study. This ...
-
July 27, 2021 — Medtronic announced new data from the landmark WRAP-IT study published in Heart Rhythm,[1] demonstrating a significantly lower infection risk for patients who develop hematomas after ...
October 1, 2021 — The European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization ...
October 04, 2021
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at ...
October 04, 2021
September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control ...
September 13, 2021
August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...
August 03, 2021
Samir Saba, M.D., co-director of the University of Pittsburgh Medical Center Heart and Vascular Institute, and chief ...
August 02, 2021
July 28, 2021 — The U.S. Justice Department announced earlier this month that St. Jude Medical Inc. agreed to pay $27 ...
July 28, 2021![Medtronic announced new data from the landmark WRAP-IT study published in Heart Rhythm,[1] demonstrating a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the Tyrx Absorbable Antibacterial Envelope is used at implant. The analysis showed an 82% reduction in major CIED infections among patients with the Tyrx Envelope who developed hematomas compared to patients in the control group who developed hematomas.](/sites/default/files/styles/content_feed_medium/public/X0000_Tyrx_AIGISRx_Envelope_with_Pacemaker.jpg?itok=BHsWJ9_y)
July 27, 2021 — Medtronic announced new data from the landmark WRAP-IT study published in Heart Rhythm,[1] demonstrating ...
July 27, 2021
June 2, 2021 — Implicity, a leader in remote patient monitoring software and cardiac data management solutions ...
June 02, 2021
May 14, 2021 — The U.S. Food and Drug Administration (FDA) is advising patients and caregivers to keep any consumer ...
May 14, 2021
May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of ...
May 06, 2021
April 12, 2021 — Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac ...
April 12, 2021
April 2, 2021 — Today, the American College of Cardiology (ACC) launched the Electrophysiology (EP) Device Implant ...
April 02, 2021
A few weeks ago, a patient of mine experienced a cardiac event — his heart stopped. Completely. However, his implantable ...
March 17, 2021
March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...
March 03, 2021
January 8, 2020 — A new study published this week in HeartRhythm, the journal of the Heart Rhythm Society (HRS), found ...
January 08, 2021© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now